Introduction
============

Human hepatocellular carcinoma (HCC) is the third most common cause of mortality due to cancer and the fifth most common malignancy worldwide, with a particularly high incidence observed in Africa and Asia ([@b1-ol-0-0-8586]). Liver carcinogenesis is generally considered to be associated with inflammation caused by environmental factors, including hepatitis B and C viral infections, which are the major risk factors of HCC ([@b2-ol-0-0-8586],[@b3-ol-0-0-8586]).

Toll-like receptor 4 (TLR4) is a well-studied member of the TLR protein family. Lipopolysaccharide (LPS) released from bacteria can bind to TLR4, leading to the activation of TLR4 and myeloid differentiation primary response 88 (MyD88). Signaling via TLR4/MyD88 initiates the activation of nuclear factor-κB (NF-κB) and a subsequent expression of pro-inflammatory genes that trigger the host inflammatory response to infection ([@b4-ol-0-0-8586],[@b5-ol-0-0-8586]). TLR4 is overexpressed in various types of human cancer, including breast cancer, melanoma, colon cancer, ovary cancer and prostate cancer ([@b6-ol-0-0-8586]--[@b10-ol-0-0-8586]). TLR4 expression and activation of the TLR4/MyD88-mediated signaling pathways promote carcinogenesis and metastasis ([@b11-ol-0-0-8586],[@b12-ol-0-0-8586]). Furthermore, it has been demonstrated that TLR4 contributes to the growth and migration of hepatocellular tumors ([@b13-ol-0-0-8586],[@b14-ol-0-0-8586]).

An inflammatory microenvironment is a hallmark of tumor-associated inflammation ([@b15-ol-0-0-8586]). Chronic inflammation induces DNA damage and oncogenic mutations, causing cancer formation and progression ([@b16-ol-0-0-8586]--[@b18-ol-0-0-8586]). Interleukin (IL)-23, a member of the IL-12 family, is a heterodimeric pro-inflammatory cytokine that is mainly produced by inflammatory myeloid cells. IL-23 stimulates T cells to differentiate into T helper 17 (Th17) cells in the presence of IL-6 and transforming growth factor-β ([@b19-ol-0-0-8586]). Th17 cells are a population of T helper lymphocytes, and include the subtypes of IL-17A, IL-17B, IL-17C, IL-17D, IL-17E/IL-25 and IL-17F. These cells are able to produce another pro-inflammatory cytokine, IL-17 ([@b20-ol-0-0-8586]). IL-17 recruits neutrophils, enhances dendritic cell maturation and stimulates macrophages to produce IL-1β and tumor necrosis factor (TNF)-α, which then induce and mediate pro-inflammatory responses ([@b21-ol-0-0-8586]). An increasing number of studies demonstrated that the IL-23/IL-17A axis contributes to cancer growth and metastasis. Furthermore, this axis can reduce the infiltration of CD8^+^ cells in tumors and enhance the immunosuppressive activity of regulatory T cells ([@b22-ol-0-0-8586],[@b23-ol-0-0-8586]).

In the present study, the expression of TLR4 in HCC tissues and its correlation with the clinical features of HCC was analyzed. In addition, the correlation between TLR4 expression and the IL-23/IL-17A axis in HCC were examined in order to determine whether IL-23 and IL-17A serve a role in its carcinogenesis.

Materials and methods
=====================

### Chemicals

Primers were synthesized by SBS Genetech Co., Ltd. (Beijing, China). The primary antibodies against TLR4 (dilution 1:400; cat. no. ab13556), IL-23 (dilution 1:400; cat. no. ab45420), IL-17A (dilution 1:200; cat. no. ab136668) and β-actin (dilution 1:1,000; cat. no. ab8227) were all purchased from Abcam (Cambridge, UK). ELISA kits for the detection of IL-23 (cat. no. F0153) and IL-17A (cat. no. F01451) levels were provided by Westang Biological Technology Co., Ltd. (Shanghai, China). LPS was obtained from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany), while the MyD88 inhibitor ST2825 was from MedChemExpress (Monmouth Junction, NJ, USA). TRIzol^®^ reagent, fetal bovine serum (FBS), Dulbecco\'s modified Eagle\'s medium (DMEM), and the SYBR-Green PCR Master Mix, bicinchoninic acid (BCA) and enhanced chemiluminescence (ECL) kits were purchased from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). The reverse transcription (RT) kit was supplied by Promega Corporation (Madison, WI, USA).

### Cell culture

Human liver cancer HepG2 cells were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in DMEM supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 g/ml) in a humidified atmosphere containing 5% CO~2~ at 37°C.

### Human tissues

The application of clinical samples was reviewed and approved by the Ethics Committee of Ningxia Medical University (Yinchuan, China), and patients provided written informed consent. Based on the National Standard for Diagnosis and Treatment of Primary Liver Cancer (2011 edition) guidelines ([@b24-ol-0-0-8586]), 45 paraffin-embedded tissue samples of primary HCC from patients who had not received radiotherapy or chemotherapy prior to surgery were collected at the General Hospital of Ningxia Medical University between October 2012 and December 2014. The patients were graded on the basis of the tumor-node-metastasis (TNM) stage ([@b25-ol-0-0-8586]). There were 17 adjacent normal tissues also collected and served as the controls. All the samples were embedded in paraffin and stored at 4°C after sectioning.

### Immunohistochemical assay

Tissue sections (thickness, 4 µm) were deparaffinized in xylene, soaked in alcohol and treated in antigen unmasking solution (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China) in the microwave for 10 min, followed by incubation in 3% hydrogen peroxide for 10 min to inactivate the endogenous peroxidase. The sections were then incubated with antibodies against TLR4, IL-23, IL-17A and β-actin at 4°C overnight. Immunostaining was performed using the Histostain^™^-Plus kit (cat. no. 859073; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s instructions. Two independent researchers evaluated each stained section. Immunohistochemical staining was evaluated by the intensity and distribution of cytoplasmic staining. Staining intensity was graded as follows: 0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining. Staining distribution was based on the percentage of stained tumor cells: 0, 0%; 1, \<25%; 2, 25--50%; 3, 51--75% and 4, \>75% ([@b26-ol-0-0-8586]). The final staining scores were calculated as follows: Staining intensity × the percentage of stained tumor cells.

### ELISA

Cells were seeded in 96-well plates at a density of 5×10^4^ cells/well and cultured for 24 h, followed by exposure to 1 mg/l LPS for 12, 24 or 36 h alone or pretreated with 40 µmol/l ST2825 for 8 h, prior to being treated with 1 mg/l LPS for 12, 24 or 36 h. The control cells were cultured with DMEM. The supernatant was centrifuged at 12,000 × g for 5 min at 4°C and the concentration of IL-23 and IL-17A in the culture medium was measured by an ELISA kit, according to the manufacturer\'s instructions. The absorbance was then detected spectrophotometrically at 450 nm using a microplate reader and plotted against a standard curve with standard levels expressed as pg/ml. Each sample was analyzed in triplicate.

### RNA extraction and RT-quantitative polymerase chain reaction (qPCR)

HepG2 cells were treated with LPS (1 mg/l) for 24 h, alone or followed by ST2825 (40 µmol/l) treatment for 8 h. The control cells were cultured with DMEM. Total RNA was extracted from HepG2 cells by TRIzol reagent, and further purified using RNeasy Mini columns (cat no. 74104; Qiagen GmbH, Hilden, Germany). Complementary DNA (cDNA) was then synthesized using a high-capacity cDNA reverse transcription kit. Subsequently, qPCR assays were performed in triplicate using SYBR^®^ Green PCR Master Mix with the following thermal cycling conditions: 95°C for 10 min, 40 cycles of denaturation at 95°C for 15 sec, annealing at 60°C for 30 sec and extension at 72°C for 30 sec. The sequences of primers used in the qPCR assay are listed in [Table I](#tI-ol-0-0-8586){ref-type="table"}. The relative mRNA expression of HepG2 cells was calculated using the 2^−ΔΔCq^ method ([@b27-ol-0-0-8586]), and normalized using GAPDH as the reference gene.

### Western blot analysis

HepG2 cells were treated with the 40 µmol/l ST2825 and 1 mg/l LPS for 24 h. The control cells were cultured with DMEM. Next, cells were lysed in a radioimmunoprecipitation assay buffer containing 1% NP-40, 150 mM NaCl, 50 mM Tris-HCl, 50 mM NaF and 1 mM Na~3~VO~4~. The protein concentration in the cell lysate was determined using a BCA Protein Assay kit. A total of 40 µg protein was then separated via 20% SDS-PAGE, followed by transfer to a nitrocellulose membrane. The membranes were blocked with 5% milk in Tris-buffered saline/Tween-20 (TBST) buffer at 4°C overnight and probed with primary antibodies against TLR4, IL-23 or IL-17A, and β-actin was used as the internal control. Membranes were subsequently washed three times with TBST for 5 min each and incubated with a horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. Following washing five times with 1X TBST for 5 min each time, the membranes were developed with ECL detection reagents, and the signal intensity was quantified by ImageJ (version 1.45s; National Institutes of Health, Bethesda, MD, USA).

### Statistical analysis

All statistical analyses were performed with SPSS version 17.0 software (SPSS, Inc., Chicago, IL, USA). Quantitative variables are presented as the mean ± standard deviation, and were analyzed with the Student\'s t-test, one-way analysis of variance, χ^2^ test or Pearson\'s correlation coefficient. P\<0.05 was considered to indicate statistically significant differences.

Results
=======

### TLR4 expression is upregulated in HCC tissues

TLR4 is a receptor that serves an important role in inflammation ([@b28-ol-0-0-8586]). The expression of TLR4 has been identified in several types of cancer, including liver, breast, colon, ovarian and prostate cancer, and melanoma, and its expression contributes to carcinogenesis ([@b6-ol-0-0-8586]--[@b10-ol-0-0-8586],[@b13-ol-0-0-8586]). In order to determine whether TLR4 is involved in the development of HCC, the expression of TLR4 in HCC tissues obtained from patients was assessed. Immunohistochemical staining with TLR4 antibody revealed that TLR4 was expressed in the cytoplasm and cell surface of cancer cells in the tissue sections, as observed by yellow and brown staining ([Fig. 1](#f1-ol-0-0-8586){ref-type="fig"}). The positive rate of TLR4 in HCC tissues was 77.8% (35/45; [Table II](#tII-ol-0-0-8586){ref-type="table"}), while this rate was only 20% in adjacent noncancerous tissues, suggesting an upregulation of TLR4 expression in HCC.

### TLR4 expression is correlated with HCC clinicopathological characteristics

To further examine whether TLR4 expression in HCC serves a role in the carcinogenesis, the correlation between TLR4 expression and the clinicopathological characteristics of HCC patients was analyzed. As shown in [Table II](#tII-ol-0-0-8586){ref-type="table"}, there was no significant correlation of TLR4 expression with the age, tumor size or tumor differentiation of patients (P\>0.05). However, high expression of TLR4 was correlated with sex and a lower TNM stage (P\<0.05; [Table II](#tII-ol-0-0-8586){ref-type="table"}), suggesting that TLR4 expression may contribute to the development of HCC.

### TLR4 expression is correlated with the expression levels of IL-17A and IL-23 in HCC

IL-17A and IL-23 are key mediators of inflammation that contribute to carcinogenesis ([@b29-ol-0-0-8586],[@b30-ol-0-0-8586]). In order to establish whether TLR4 promotes carcinogenesis through IL-17A and IL-23 regulation, the correlation between TLR4 expression and the levels of IL-17A and IL-23 was examined. The results identified that the expression of TLR4 was associated with the levels of IL-17A (R=0.583) and IL-23 (R=0.634) in HCC ([Table II](#tII-ol-0-0-8586){ref-type="table"}), indicating a possible regulation effect between the expression of TLR4 and that of IL-17A and IL-23.

### Expression levels of IL-23 and IL-17A are regulated by TLR4/MyD88 in HCC cells

TLR4 is a receptor expressed in all cell types in the liver, including hepatocytes cells, and is able to recognize LPS from the bacterial wall. Activation of TLR4 triggers an inflammatory response through MyD88-mediated activation of downstream signaling pathways ([@b4-ol-0-0-8586],[@b5-ol-0-0-8586]). As TLR4 expression was correlated with IL-23 and IL-17A expression in HCC tumors, as discussed earlier, the study further examined whether activation of the TLR4/MyD88 pathway regulates the expression levels of IL-23 and IL-17A proteins. As determined by western blot analysis, LPS induced the activation of TLR4, leading to enhanced expression of IL-23 and IL-17A in HCC cells. The expression of these interleukins was subsequently blocked by incubation with the MyD88 inhibitor, ST2825, and showed a time-dependent effect ([Fig. 2](#f2-ol-0-0-8586){ref-type="fig"}). Analysis of IL-23 and IL-17A levels using an ELISA assay further confirmed this result, indicating that the expression levels of IL-23 and IL-17A were regulated by the TLR4/MyD88 signaling pathway in HCC cells ([Fig. 2](#f2-ol-0-0-8586){ref-type="fig"}).

### TLR4/MyD88 signaling pathway regulates the transcription of IL-23 and IL-17A

Enhanced gene expression may be due to the upregulation of gene transcription. Using RT-qPCR, it was observed that LPS treatment of HepG2 cells resulted in enhanced transcription of IL-23 and IL-17A, while this upregulation of gene transcription was then blocked upon incubation with a MyD88 inhibitor ([Fig. 3](#f3-ol-0-0-8586){ref-type="fig"}). These findings indicated that activation of the TLR4/MyD88 signaling pathway enhances the expression of IL-23 and IL-17A through the upregulation of gene transcription.

### Activation of TLR4/MyD88 enhances TLR4 expression

The present study further examined whether activation of TLR4 regulates the expression of itself. RT-qPCR and western blot analyses revealed that stimulation of HepG2 cells with the TLR4-ligand LPS enhanced the expression levels of TLR4 mRNA and protein, whereas application of the MyD88 inhibitor blocked the upregulation of TLR4 expression induced by LPS. These results indicate a positive feedback loop of TLR4 activation and its expression ([Fig. 4](#f4-ol-0-0-8586){ref-type="fig"}).

### Expression levels of IL-23 and IL-17A are correlated with the HCC clinicopathological characteristics

Since the expression of TLR4 was correlated with the clinical features of HCC, and activation of TLR4 was observed to upregulate the expression levels of IL-23 and IL-17A, the current study further investigated whether the levels of IL-23 and IL-17A are also correlated with the clinical features of HCC. Analysis of the protein expression levels of IL-23 and IL-17A in HCC tumor tissues and adjacent normal tissues indicated that they were associated with sex, lymph node metastasis and the TNM stages of HCC (P\<0.05). By contrast, no association was detected between these protein levels and the patient age, tumor size and tumor differentiation (P\>0.05), as shown in [Table II](#tII-ol-0-0-8586){ref-type="table"}.

Discussion
==========

Chronic inflammation is associated with the initiation, development and progression of carcinomas, and may contribute to cancer progression by activating angiogenesis and oncogenic signaling pathways ([@b31-ol-0-0-8586]). It is well known that HCC is a long-term consequence of chronic inflammatory liver diseases ([@b32-ol-0-0-8586]). In the present study, it was demonstrated that TLR4, IL-23 and IL-17A, which are involved in inflammation, were highly expressed in carcinoma tissues. In addition, the expression levels of TLR4, IL-23 and IL-17A were associated with lymph node metastasis and the TNM stages of HCC. It has previously been reported that the expression of TLR4 and MyD88 may be associated with breast cancer growth and distant metastases ([@b6-ol-0-0-8586]). In another study, Grivennikov *et al* ([@b33-ol-0-0-8586]) observed that IL-23 signaling promoted tumor growth and progression, as well as the development of a tumoral IL-17 response. The current study finding further supported the important role of the TLR4/MyD88 signaling pathway and IL-23/IL-17A in cancer.

The TLR4/MyD88 pathway mediates the activation of NF-κB and subsequent production of pro-inflammatory cytokines, including IL-1β, IL-6 and TNF-α. These cytokines stimulate myeloid dendritic cells to secret IL-23, which promotes Th17 cell differentiation, proliferation and maintenance ([@b34-ol-0-0-8586],[@b35-ol-0-0-8586]). It has been reported that the IL-23/IL-17A axis promotes the formation of lung metastases through tumor-endothelial transmigration ([@b36-ol-0-0-8586]). In the present study, it was observed that the expression of TLR4 was associated with the expression levels of IL-17A (R=0.583) and IL-23 (R=0.634). To determine the possible role of the TLR4/MyD88 pathway and the IL-23/IL-17A axis in HCC, the study measured the TLR4, IL-23 and IL-17A expression levels in HepG2 cells stimulated with LPS using RT-qPCR and western blot analyses. The results revealed that LPS promoted the mRNA transcription and protein expression levels of TLR4, IL-23 and IL-17A in HepG2 cell lines, which were subsequently inhibited by incubation with the MyD88 inhibitor ST2825. Teng *et al* ([@b37-ol-0-0-8586]) previously reported that IL-23 was induced in response to stimulation by multiple TLR ligands, and this cytokine has been linked to autoimmune and inflammatory diseases. IL-23 consists of p19 and p40 units, while Brentano *et al* ([@b38-ol-0-0-8586]) further observed that the induction of p19 was TLR-dependent. In the present study, the data revealed that TLR4/MyD88 signaling regulated the expression levels of IL-23 and IL-17A in hepatocellular tumor cells.

In conclusion, the current study identified that the TLR4/MyD88 signaling pathway may be involved in hepatocellular carcinogenesis via upregulating the IL-23/IL-17A axis, and that it may serve as an important therapeutic target of HCC.
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![Immunohistochemical staining of TLR4, IL-23 and IL-17A in HCC tissues was observed using a microscope (×400 magnification). The arrow indicates the positive yellow and brown staining for these proteins. (A) Adjacent non-cancerous tissues. (B) TLR4, (C) IL-23 and (D) IL-17A expression in HCC tissue. TLR4, Toll-like receptor 4; IL, interleukin; HCC, hepatocellular carcinoma.](ol-15-06-9647-g00){#f1-ol-0-0-8586}

![LPS promotes IL-23 and IL-17A expression in HepG2 cells, as measured by enzyme-linked immunosorbent assay. HepG2 cells were treated with 1 mg/l LPS for 12, 24 or 36 h, or pretreated with 40 µmol/l ST2825 for 8 h, followed by treatment with 1 mg/l LPS for 12, 24 or 36 h. The concentration of IL-23 and IL-17A in the culture medium was quantified by measuring the absorbance at 450 nm with a microplate reader. Results are representative of three independent experiments. \*P\<0.05 and \*\*P\<0.01 vs. control group. LPS, lipopolysaccharide; IL, interleukin.](ol-15-06-9647-g01){#f2-ol-0-0-8586}

![LPS promotes the mRNA expression levels of (A) TLR4, (B) IL-23 and (C) IL-17A, as determined by RT-qPCR. HepG2 cells were treated with 1 mg/l LPS for 24 h, or were pretreated with 40 µmol/l ST2825 for 8 h, followed by treatment with 1 mg/l LPS for 24 h. \*P\<0.05 vs. control group. TLR4, Toll-like receptor 4; IL, interleukin; LPS, lipopolysaccharide.](ol-15-06-9647-g02){#f3-ol-0-0-8586}

![LPS promotes the protein expression levels of (A) TLR4, (B) IL-17A and (C) IL-23 as demonstrated by the quantified results. (D) Western blots of TLR4, IL-23 and IL-17A protein levels are also shown. HepG2 cells were treated with 1 mg/l LPS alone for 24 h, or pretreated with 40 µmol/l ST2825 for 8 h, followed by treatment with 1 mg/l LPS for 24 h. \*P\<0.05 vs. control group. TLR4, Toll-like receptor 4; IL, interleukin; LPS, lipopolysaccharide.](ol-15-06-9647-g03){#f4-ol-0-0-8586}

###### 

Sequences of primers used in quantitative polymerase chain reaction assay.

  Genes    Primer sequence (5′-3′)
  -------- -------------------------
  TLR4     F: GCAGTTTCTGAGCAGTCGTG
           R: CTGTCCTCCCACTCCAGGTA
  IL-23    F: GCCTTCTCTGCTCCCTGATA
           R: GACTGAGGCTTGGAATCTGC
  IL-17A   F: CGATCCACCTCACCTTGGAA
           R: TAGTCCACGTTCCCATCAGC
  GAPDH    F: CAATGACCCCTTCATTGACC
           R: GACAAGCTTCCCGTTCTCAG

TLR4, Toll-like receptor 4; IL, interleukin; F, forward; R, reverse.

###### 

Statistical analysis of TLR4, IL-23 and IL-17A expression and clinicopathological factors in hepatocellular carcinoma.

                          TLR4   IL-23        IL-17A                                                                                          
  ----------------------- ------ ------------ -------- ------- ---- ------------ -------- -------- ------- ---- ------------ ------- -------- -------
  Cancer patients         45     35 (77.8%)   8.916    0.003   45   32 (71.1%)   14.347   0.0002   0.634   45   30 (66.7%)   11.9    0.0005   0.583
  Control tissues         17     5 (29.4%)                     17   3 (17.6%)                              17   3 (17.6%)                     
  Age, years                                                                                                                                  
    ≤50                   20     15           0.265    0.607   19   12           1.013    0.314            17   10           0.756   0.384    
    \>50                  25     17                            26   20                                     28   20                            
  Sex                                                                                                                                         
    Male                  39     33           7.912    0.005   37   30           10.07    0.002            38   29           6.287   0.012    
    Female                6      2                             8    2                                      7    2                             
  Tumor size, cm                                                                                                                              
    ≤5                    27     23           2.143    0.143   25   18           0.022    0.883            25   18           0.72    0.396    
    \>5                   18     12                            20   14                                     20   12                            
  Tumor metastasis                                                                                                                            
    Positive              20     15           5.513    0.019   30   25           6.545    0.01             34   25           5.01    0.025    
    Negative              25     10                            15   7                                      11   4                             
  TNM stage                                                                                                                                   
    T1+T2                 25     18           4.36     0.037   27   9            4.821    0.028            26   6            4.185   0.041    
    T3+T4                 20     17                            18   12                                     19   10                            
  Tumor differentiation                                                                                                                       
    High                  25     18           1.086    0.297   27   21           6.682    0.409            26   20           2.915   0.088    
    Poor                  20     17                            18   12                                     19   10                            

Indicates the number of patients with positive expression.
